[Assessment of the mutagenic activity of aversectin C].
Aversectin C was evaluated for mutagenic activity in the Ames test with Salmonella typhimurium TA 97, TA 98 and TA 100, in the dominant lethal assay on uninbred albino rats in a dose of 2.25 mg/kg body weight (1/40 of the LD50) and in the metaphase test on F1CBAxC57BI/6 mice in a dose of 8.2 mg/kg body weight (1/5 of the LD50). The agent showed no mutagenic activity in any of the tests. The anaphase test on F1CBAxC57BI/6 mice revealed no antimitotic activity of aversectin C.
Novik
T S
TS
NPO Farmbiomed, Moscow.
Baru
R V
RV
Riabova
V A
VA
Piatova
V A
VA
Driniaev
V A
VA
Chukina
S I
SI
Krugliak
E B
EB
Mosin
V A
VA
D000705:Anaphase / Q000187:drug effects; D000818:Animals; D000900:Anti-Bacterial Agents / Q000633:toxicity*; D001854:Bone Marrow Cells / Q000187:drug effects; D007559:Ivermectin / Q000031:analogs & derivatives* / Q000633:toxicity; D007928:Lethal Dose 50; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008808:Mice, Inbred CBA; D008938:Mitosis / Q000187:drug effects; D009152:Mutagenicity Tests; D009153:Mutagens / Q000633:toxicity*; D051381:Rats; D012486:Salmonella typhimurium / Q000235:genetics
D000900:Anti-Bacterial Agents; D009153:Mutagens; D007559:Ivermectin; C019264:avermectin